Almac Partners with Optel to Launch Serialization Solution

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-04-2016
Volume 11
Issue 5

Almac partnered with Optel Vision to provide a line-level solution (hardware and software) integrated with Almac’s proprietary level three, site-level software.

Almac Group, a global contract development and manufacturing organization, announced on April 25, 2016 its plans to expand serialization capabilities to include its United States commercial packaging facility in Audubon, PA. Building upon Almac’s in-house proprietary serialization/track-and-trace solution developed at its United Kingdom headquarters, this technology expansion will address FDA regulations, meeting the requirements outlined in the Drug Quality and Security Act, the company said in a press announcement. Almac partnered with Optel Vision to provide a line-level solution (hardware and software) integrated with Almac’s proprietary level three, site-level software. This new serialization solution is a high-spec standalone line that prints, verifies, and aggregates saleable packs to the pallet with reporting functionality.

“We knew Almac had its own in-house solution for the UK and for the first Almac serialization project in the US, we combined the knowledge of both companies to design a solution that meets Almac quality standards as well as the demand from global markets using the Optel Vision hardware and software solutions, said Yvon Lemay, Optel Vision project manager. “The system is now operational and can be easily scalable for future needs.”

Source: Almac

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content